Rapid deep sequencing of patient-derived HIV with ion semiconductor technology

Journal of Virological Methods

Volumn 189, Issue 1, 2013, Pages 232-234

  Chang, Max W ^a   Oliveira, Glenn ^b   Yuan, Jinyun ^a,e   Okulicz, Jason F ^c,d   Levy, Samuel ^b,f   Torbett, Bruce E ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^e SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Genomic Health Inc   (United States)

Author keywords

Deep sequencing; HIV Gag; HIV protease; HIV 1 drug resistance; Ion Torrent

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; COMPLEMENTARY DNA; DIDANOSINE PLUS LAMIVUDINE; EFAVIRENZ; LAMIVUDINE PLUS TENOFOVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD SAMPLING; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ION SEMICONDUCTOR SEQUENCING; NONHUMAN; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; SEMICONDUCTOR; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS MUTATION; VIRUS PARTICLE; VIRUS REPLICATION;

ANTI-HIV AGENTS; BASE SEQUENCE; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENES, GAG; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HUMANS; MUTATION; RNA, VIRAL; SEQUENCE ANALYSIS, RNA;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875507913     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2013.01.019     Document Type: Article

References (16)

1. Archer J., Baillie G., Watson S.J., Kellam P., Rambaut A., Robertson D.L. Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II. BMC Bioinformatics 2012, 13:47.
2. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int. J. Antimicrob. Agents 2009, 33:307-320.
3. Fun A., Wensing A.M., Verheyen J., Nijhuis M. Human immunodeficiency virus gag and protease: partners in resistance. Retrovirology 2012, 9:63.
4. Glenn T.C. Field guide to next-generation DNA sequencers. Mol. Ecol. Resour. 2011, 11:759-769.
5. Harismendy O., Frazer K. Method for improving sequence coverage uniformity of targeted genomic intervals amplified by LR-PCR using Illumina GA sequencing-by-synthesis technology. Biotechniques 2009, 46:229-231.
6. Henn M.R., Boutwell C.L., Charlebois P., Lennon N.J., Power K.A., Macalalad A.R., Berlin A.M., Malboeuf C.M., Ryan E.M., Gnerre S., Zody M.C., Erlich R.L., Green L.M., Berical A., Wang Y., Casali M., Streeck H., Bloom A.K., Dudek T., Tully D., Newman R., Axten K.L., Gladden A.D., Battis L., Kemper M., Zeng Q., Shea T.P., Gujja S., Zedlack C., Gasser O., Brander C., Hess C., Gunthard H.F., Brumme Z.L., Brumme C.J., Bazner S., Rychert J., Tinsley J.P., Mayer K.H., Rosenberg E., Pereyra F., Levin J.Z., Young S.K., Jessen H., Altfeld M., Birren B.W., Walker B.D., Allen T.M. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Path. 2012, 8:e1002529.
7. Johnson V.A., Calvez V., Gunthard H.F., Paredes R., Pillay D., Shafer R., Wensing A.M., Richman D.D. 2011 update of the drug resistance mutations in HIV-1. Top. Antivir. Med. 2011, 19:156-164.
8. HIV Sequence Compendium Theoretical Biology and Biophysics Group 2010, Los Alamos National Laboratory, New Mexico. C. Kuiken, B. Foley, T. Leitner, C. Apetrei, B. Hahn, I. Mizrachi, J. Mullins, A. Rambaut, S. Wolinsky, B. Korber (Eds.).
9. Kutilek V.D., Sheeter D.A., Elder J.H., Torbett B.E. Is resistance futile?. Curr. Drug. Targets Infect. Disord. 2003, 3:295-309.
10. Loman N.J., Misra R.V., Dallman T.J., Constantinidou C., Gharbia S.E., Wain J., Pallen M.J. Performance comparison of benchtop high-throughput sequencing platforms. Nat. Biotechnol. 2012, 30:434-439.
11. Macalalad A.R., Zody M.C., Charlebois P., Lennon N.J., Newman R.M., Malboeuf C.M., Ryan E.M., Boutwell C.L., Power K.A., Brackney D.E., Pesko K.N., Levin J.Z., Ebel G.D., Allen T.M., Birren B.W., Henn M.R. Highly sensitive and specific detection of rare variants in mixed viral populations from massively parallel sequence data. PLoS Comp. Biol. 2012, 8:e1002417.
12. Palmer S., Kearney M., Maldarelli F., Halvas E.K., Bixby C.J., Bazmi H., Rock D., Falloon J., Davey R.T., Dewar R.L., Metcalf J.A., Hammer S., Mellors J.W., Coffin J.M. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43:406-413.
13. Shafer R.W., Rhee S.Y., Pillay D., Miller V., Sandstrom P., Schapiro J.M., Kuritzkes D.R., Bennett D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007, 21:215-223.
14. Wang C., Mitsuya Y., Gharizadeh B., Ronaghi M., Shafer R.W. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 2007, 17:1195-1201.
15. Zagordi O., Bhattacharya A., Eriksson N., Beerenwinkel N. ShoRAH: estimating the genetic diversity of a mixed sample from next-generation sequencing data. BMC Bioinformatics 2011, 12:119.
16. Zagordi O., Klein R., Daumer M., Beerenwinkel N. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res. 2010, 38:7400-7409.